A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 31/7105 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C07K 14/575 (2006.01) C07K 14/705 (2006.01) C07K 16/18 (2006.01) G01N 33/53 (2006.01) G01N 33/567 (2006.01)
Patent
CA 2370252
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
La présente invention concerne des protocoles thérapeutiques et des compositions pharmaceutiques destinés à traiter et prévenir le cancer. L'invention se rapporte, en particulier, à un nouveau procédé permettant de traiter le cancer à l'aide d'antagonistes du récepteur de l'endothéline B (ETB) ou à des formes mimétiques inactives de l'endothéline 1. Les compositions pharmaceutiques de l'invention sont capables d'inhiber sélectivement les événements précoces associés au développement du cancer. L'invention concerne en outre des analyses de criblage permettant d'identifier des composés qui inhibent l'activation de l'ETB.
Jamal Sumayah
Schneider Robert J.
New York University
Osler Hoskin & Harcourt Llp
LandOfFree
Cancer treatment with endothelin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatment with endothelin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment with endothelin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1759725